Total Payments
$1,201
2020 Payments
$39.23
Companies
8
Transactions
45
Medicare Patients
402
Medicare Billing
$53,362
Payment Breakdown by Category
Food & Beverage$1,171 (97.5%)
Education$29.99 (2.5%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,171 | 44 | 97.5% |
| Education | $29.99 | 1 | 2.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Sunovion Pharmaceuticals Inc. | $398.66 | 11 | $0 (2019) |
| Alkermes, Inc. | $263.80 | 5 | $0 (2018) |
| Allergan Inc. | $245.82 | 9 | $0 (2018) |
| Janssen Pharmaceuticals, Inc | $134.38 | 10 | $0 (2019) |
| Teva Pharmaceuticals USA, Inc. | $113.02 | 7 | $0 (2020) |
| Otsuka America Pharmaceutical, Inc. | $20.64 | 1 | $0 (2017) |
| Neurocrine Biosciences, Inc. | $13.75 | 1 | $0 (2017) |
| Lundbeck LLC | $11.12 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2020 | $39.23 | 1 | Teva Pharmaceuticals USA, Inc. ($39.23) |
| 2019 | $203.85 | 8 | Sunovion Pharmaceuticals Inc. ($138.35) |
| 2018 | $354.07 | 18 | Sunovion Pharmaceuticals Inc. ($156.00) |
| 2017 | $604.04 | 18 | Alkermes, Inc. ($240.21) |
All Payment Transactions
45 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/04/2020 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | Food and Beverage | In-kind items and services | $39.23 | General |
| Category: Central Nervous System | ||||||
| 10/08/2019 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Food and Beverage | In-kind items and services | $14.20 | General |
| Category: CNS | ||||||
| 09/18/2019 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Food and Beverage | In-kind items and services | $23.00 | General |
| Category: CNS | ||||||
| 08/14/2019 | Janssen Pharmaceuticals, Inc | INVEGA TRINZA (Drug) | Food and Beverage | In-kind items and services | $11.28 | General |
| Category: Neuroscience | ||||||
| 06/13/2019 | Janssen Pharmaceuticals, Inc | INVEGA TRINZA (Drug) | Food and Beverage | In-kind items and services | $15.46 | General |
| Category: Neuroscience | ||||||
| 06/10/2019 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Food and Beverage | In-kind items and services | $101.15 | General |
| Category: CNS | ||||||
| 05/15/2019 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $11.29 | General |
| Category: Neuroscience | ||||||
| 02/20/2019 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $15.65 | General |
| Category: Neuroscience | ||||||
| 01/16/2019 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $11.82 | General |
| Category: Neuroscience | ||||||
| 12/19/2018 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Food and Beverage | In-kind items and services | $19.79 | General |
| Category: CNS | ||||||
| 11/14/2018 | Allergan Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.22 | General |
| Category: NEUROSCIENCE | ||||||
| 11/13/2018 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | Food and Beverage | In-kind items and services | $14.17 | General |
| Category: Central Nervous System | ||||||
| 10/18/2018 | Alkermes, Inc. | Aristada 441 mg (Drug), Aristada 662mg, Aristada 882mg | Food and Beverage | In-kind items and services | $23.59 | General |
| Category: CNS | ||||||
| 10/09/2018 | Janssen Pharmaceuticals, Inc | INVEGA TRINZA (Drug) | Food and Beverage | In-kind items and services | $16.24 | General |
| Category: Neuroscience | ||||||
| 09/26/2018 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Food and Beverage | In-kind items and services | $22.14 | General |
| Category: CNS | ||||||
| 09/14/2018 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | Food and Beverage | In-kind items and services | $11.99 | General |
| Category: Central Nervous System | ||||||
| 08/07/2018 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | Food and Beverage | In-kind items and services | $11.99 | General |
| Category: Central Nervous System | ||||||
| 05/17/2018 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $13.40 | General |
| Category: Neuroscience | ||||||
| 05/08/2018 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $11.12 | General |
| Category: PSYCHIATRY | ||||||
| 05/07/2018 | Allergan Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.51 | General |
| Category: NEUROSCIENCE | ||||||
| 04/26/2018 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Food and Beverage | In-kind items and services | $8.39 | General |
| Category: CNS | ||||||
| 04/02/2018 | Allergan Inc. | VRAYLAR (Drug) | Education | In-kind items and services | $29.99 | General |
| Category: NEUROSCIENCE | ||||||
| 03/13/2018 | Allergan Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.11 | General |
| Category: NEUROSCIENCE | ||||||
| 02/28/2018 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Food and Beverage | In-kind items and services | $97.50 | General |
| Category: CNS | ||||||
| 02/12/2018 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | Food and Beverage | In-kind items and services | $11.99 | General |
| Category: Central Nervous System | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 122 | 159 | $41,225 | $12,385 |
| 2022 | 3 | 115 | 208 | $58,218 | $17,485 |
| 2021 | 3 | 81 | 174 | $41,958 | $13,610 |
| 2020 | 2 | 84 | 136 | $35,976 | $9,883 |
Total Patients
402
Total Services
677
Medicare Billing
$53,362
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 42 | 56 | $18,184 | $5,665 | 31.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 21 | 21 | $9,555 | $2,977 | 31.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 24 | 28 | $6,700 | $1,596 | 23.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 12 | 18 | $4,230 | $1,272 | 30.1% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 23 | 36 | $2,556 | $874.63 | 34.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 48 | 104 | $24,680 | $7,166 | 29.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 34 | 55 | $17,723 | $5,818 | 32.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 19 | 19 | $8,645 | $2,668 | 30.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 14 | 30 | $7,170 | $1,832 | 25.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 43 | 110 | $26,330 | $8,085 | 30.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 12 | 35 | $8,225 | $2,129 | 25.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 13 | 16 | $5,072 | $1,885 | 37.2% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2021 | 13 | 13 | $2,331 | $1,510 | 64.8% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2020 | 42 | 42 | $13,406 | $4,263 | 31.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 29 | 58 | $14,110 | $3,443 | 24.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 13 | 36 | $8,460 | $2,176 | 25.7% |
About Dr. David Post, M.D
Dr. David Post, M.D is a Psychiatry healthcare provider based in Gonzales, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1528087905.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Post, M.D has received a total of $1,201 in payments from pharmaceutical and medical device companies, with $39.23 received in 2020. These payments were reported across 45 transactions from 8 companies. The most common payment nature is "Food and Beverage" ($1,171).
As a Medicare-enrolled provider, Post has provided services to 402 Medicare beneficiaries, totaling 677 services with total Medicare billing of $53,362. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Gonzales, LA
- Active Since 07/18/2006
- Last Updated 07/08/2007
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1528087905
Products in Payments
- LATUDA (Drug) $398.66
- VRAYLAR (Drug) $245.82
- Aristada 441 mg (Drug) $244.16
- AUSTEDO (Drug) $113.02
- INVEGA SUSTENNA (Drug) $91.40
- INVEGA TRINZA (Drug) $42.98
- ABILIFY MAINTENA (Drug) $20.64
- Vivitrol 380 mg (Drug) $19.64
- INGREZZA (Drug) $13.75
- REXULTI (Drug) $11.12
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.